QIAGEN launches new library preparation kit, facilitating multiomic studies and advancing precision medicine
QIAGEN has introduced its QIAseq Multimodal DNA/RNA Lib Kit, designed to streamline the preparation of DNA and RNA libraries from a single sample for next-generation sequencing (NGS). This new kit aids multiomics studies, important for precision medicine and understanding complex diseases like cancer.
It offers a simplified workflow for whole genome and transcriptome sequencing, reducing sample material and time required. The kit supports various sample types, including blood, FFPE samples, and cfDNA, and is compatible with multiple sequencing platforms, such as Illumina and Element Aviti.
The QIAseq Multimodal Kit's flexibility in generating DNA-only or RNA-only libraries, as well as combined DNA/RNA libraries, enhances efficiency and saves resources in NGS labs. The kit adds to QIAGEN's NGS technology portfolio, which is pivotal in biomarker research and disease surveillance.
- QIAGEN's new kit simplifies DNA and RNA library preparation, reducing sample material and time.
- The QIAseq Multimodal Kit supports multiple sample types, including blood, FFPE samples, and cfDNA.
- The kit is compatible with various sequencing platforms like Illumina and Element Aviti.
- It enables generation of both DNA-only and RNA-only libraries, offering flexibility.
- The kit facilitates multiomics studies, important for precision medicine and understanding complex diseases like cancer.
- QIAGEN's QIAseq kits have processed over four million NGS samples.
- Potential market competition from other multimodal sequencing kits could impact sales.
- The need for an added conversion step for some sequencing platforms may deter some users.
- The reliance on hybrid capture panels from other providers could pose compatibility issues.
Insights
The introduction of QIAGEN's QIAseq Multimodal DNA/RNA Lib Kit is a significant leap for the field of next-generation sequencing (NGS), which is essential for various biological research areas. By enabling simultaneous DNA and RNA library preparation from a single sample, researchers can save precious sample material and reduce the time and labor involved in preparing libraries. This efficiency is particularly critical in studies involving limited sample types like Formalin-Fixed Paraffin-Embedded (FFPE) samples or cell-free DNA (cfDNA).
A notable feature of the new kit is its compatibility with multiple sequencing platforms, including Illumina instruments and Element Aviti. This flexibility allows researchers to choose their preferred sequencing technologies without being locked into a specific system, enhancing the adaptability of the kit. Additionally, the capability to detect rare DNA and RNA variants is beneficial in cancer research, where identifying such variants can lead to significant breakthroughs in understanding the disease.
In the realm of precision medicine, the capacity to streamline workflows and consolidate multiple processes into one kit accelerates the pace of research. Faster turnaround times and increased efficiency can lead to quicker insights into disease mechanisms and potential therapeutic targets, which is the core objective of precision medicine. For retail investors, understanding how this new kit could drive advancements in cancer research and other complex diseases underlines its potential market impact.
The QIAseq Multimodal DNA/RNA Lib Kit is poised to be a game-changer in research, especially in the context of multiomic studies. Multiomics involves the comprehensive study of several types of 'omics' data like genomics and transcriptomics simultaneously. This approach is important for deciphering the complexities of diseases such as cancer, where a single type of biomarker is often insufficient for a complete understanding. The kit's ability to facilitate comprehensive genomic profiling can significantly advance biomarker discovery and the development of targeted therapies.
Moreover, the high sensitivity of the kit in detecting rare variants means that researchers can identify potential biomarkers that might have been missed using traditional methods. This is particularly important in oncology, where early detection of rare mutations can lead to better patient outcomes. The versatility of the kit in handling various sample types, including challenging ones like FFPE, broadens its applicability in translational research. For retail investors, it's important to recognize how such innovations can drive growth in the biotech sector by enhancing research capabilities and accelerating the development of new diagnostics and therapies.
QIAseq Multimodal DNA/RNA Lib Kit enables streamlined DNA and RNA library preparation for next-generation sequencing from a single sample // New kit advances precision medicine by facilitating multiomic studies and Comprehensive Genomic Profiling, crucial for understanding complex diseases like cancer // Researchers are provided with the first multimodal sequencing kit for multiple sample types, offering high flexibility and sensitivity, saving sample material and time
Venlo, the Netherlands, May 29, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of its QIAseq Multimodal DNA/RNA Lib Kit. The new kit enables seamless preparation of DNA and RNA libraries for next-generation sequencing (NGS), such as whole genome sequencing (WGS) and whole transcriptome sequencing (WTS), as well as downstream target enrichment based on hybrid-capture from a single sample.
The QIAseq Multimodal DNA/RNA Lib Kit facilitates multiomics, the studies of several omic fields like genomics, transcriptomics and proteomics, aiming to gain a deeper understanding of biological processes and systems – something crucial for studying diseases like cancer. The kit offers a streamlined and rapid workflow to generate WGS and WTS libraries from a single sample by combining chemistry optimized for DNA and RNA simultaneously. Using traditional methods, separate workflows for DNA and RNA sequencing require a large amount of sample material, labor-intensive library preparation procedures, and long turn-around times.
“With the introduction of the QIAseq Multimodal DNA/RNA Lib Kit, we are addressing a direct need in the scientific community for a more efficient way to conduct multiomic studies,” said Nitin Sood, Senior Vice President, Head of the Life Sciences Business Area at QIAGEN. “Studying and understanding the complexity of biological systems better will facilitate identifying potential biomarkers for diseases or therapeutic targets for drug development and finally advance precision medicine and healthcare.”
Researchers can also use the QIAseq Multimodal DNA/RNA Lib Kit for generating DNA-only or RNA-only libraries. It is the first NGS multimodal kit on the market that is compatible with a wide range of input samples, including blood, Formalin-Fixed Paraffin-Embedded (FFPE) samples, and cell-free DNA (cfDNA). This is particularly relevant in translational research, such as in the study of cancers, where different types of samples may be available. The kit is highly sensitive, enabling detection of both DNA and RNA rare variants. The DNA and RNA libraries generated using the QIAseq Multimodal DNA/RNA Lib Kit are directly compatible with different sequencing platforms such as Illumina instruments and Element Aviti and can be sequenced on other sequencers with an added conversion step (Complete Genomics/MGI, Singular Genomics, and Ultima Genomics).
Additionally, the flexibility of generating DNA only or RNA only libraries, as well as DNA and RNA libraries compatible with further target enrichment by hybrid capture, consolidates an NGS lab’s multiple workflows into a single kit, saving lab resources while enhancing efficiency. For target enrichment, the QIAseq xHYB Human panels can be used for WES (Whole Exome Sequencing), or targeted sequencing with custom designed content. The libraries are also compatible with hybrid capture panels from other providers.
The new kit adds to QIAGEN's growing portfolio that harnesses the true potential of NGS in biological research by offering fast and efficient solutions that reduce turnaround times and maximize sequencing capacity. With a focus on front-end sample processing and downstream bioinformatics, QIAGEN provides innovative NGS technologies for genomics, transcriptomics, epigenomics, and metagenomics applications.
QIAGEN’s QIAseq kits have processed over four million NGS samples, enabling biomarker research, gene expression studies, viral epidemiology, and disease surveillance. From DNA and RNA sequencing to multimodal sequencing and epigenomics, the comprehensive range of QIAseq kits delivers reliable data on any sequencing instruments.
More information about QIAGEN’s genomics offering can be found here: https://www.qiagen.com/us/applications/next-generation-sequencing.
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of March 31, 2024, QIAGEN employed more than 5,900 people in over 35 locations worldwide. Further information can be found at https://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, collaborations, markets, strategy or operating results, including without limitation its expected adjusted net sales and adjusted diluted earnings results, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with management of growth and international operations (including the effects of currency fluctuations, regulatory processes and dependence on logistics), variability of operating results and allocations between customer classes, the commercial development of markets for our products to customers in academia, pharma, applied testing and molecular diagnostics; changing relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors); our ability to obtain regulatory approval of our products; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of QIAGEN's new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, weather or transportation delays, natural disasters, political or public health crises, and its impact on the demand for our products and other aspects of our business, or other force majeure events; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading “Risk Factors” contained in Item 3 of our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.
Source: QIAGEN N.V.
Category: Corporate
FAQ
What is QIAGEN's QIAseq Multimodal DNA/RNA Lib Kit?
How does QIAGEN's QIAseq Multimodal Kit benefit precision medicine?
What sample types are compatible with QIAGEN's QIAseq Multimodal Kit?
Which sequencing platforms are compatible with QIAGEN's QIAseq Multimodal Kit?
What are the key advantages of QIAGEN's QIAseq Multimodal Kit?
